Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Growth Hormone Secretion

Tesamorelin + Ipamorelin

Tesa+Ipa; long-acting GHRH + selective GHRP blend

FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend

This Tesamorelin + Ipamorelin entry draws on 3 cited sources published 1998 to 2007. The evidence available is graded FDA-Approved (component) on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .

At a glance

Class
FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend
Drug class
Growth Hormone Secretion
Structure
Co-formulated vial: ~1-2 mg Tesamorelin (44-aa hGHRH analog) + ~2 mg Ipamorelin (pentapeptide)
Route
SC injection
Half-life
Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs
Evidence tier
FDA-Approved (component)
Availability
Compounding Restricted

Mechanism of action

Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover.

Reported areas of research

Visceral adiposity reduction (Tesamorelin signal); improved sleep and recovery; cleaner side-effect profile than CJC-DAC blends; favoured for HIV-lipodystrophy-adjacent body composition goals

Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.

Dosage protocols reported in literature

1 mg Tesamorelin + 200 mcg Ipamorelin SC nightly (5 nights/wk). Cycle 12-16 weeks on / 4-6 weeks off

Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.

Known concerns and limitations

Tesamorelin component carries FDA-label pancreatitis and hyperglycaemia warnings; injection-site reactions; theoretical IGF-1 elevation; cost is high (Tesamorelin compounded form is expensive)

Compared with

Tesamorelin + Ipamorelin has published head-to-head comparisons with 10 compounds that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.

Frequently asked questions

What dosing is reported for Tesamorelin + Ipamorelin in research literature?

Published peptide research reports the following dosing approach for Tesamorelin + Ipamorelin: 1 mg Tesamorelin + 200 mcg Ipamorelin SC nightly (5 nights/wk). Cycle 12-16 weeks on / 4-6 weeks off. This is a research reference, not a clinical recommendation.

How is Tesamorelin + Ipamorelin administered in research?

Tesamorelin + Ipamorelin is administered via the following routes in published studies: SC injection.

What is the reported half-life of Tesamorelin + Ipamorelin?

The reported half-life of Tesamorelin + Ipamorelin is Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs.

Is Tesamorelin + Ipamorelin FDA-approved?

Not as a combination. Tesamorelin + Ipamorelin combines compounds of which only one is FDA-approved, and the combination itself has no FDA approval. PeptideHelper.org catalog status: Compounding Restricted.

What level of evidence supports Tesamorelin + Ipamorelin?

The current evidence base for Tesamorelin + Ipamorelin is best characterised as: FDA-Approved (component). See the methodology page for the full evidence-tier rubric.

What side effects are reported for Tesamorelin + Ipamorelin?

Known concerns reported in the literature for Tesamorelin + Ipamorelin include: Tesamorelin component carries FDA-label pancreatitis and hyperglycaemia warnings; injection-site reactions; theoretical IGF-1 elevation; cost is high (Tesamorelin compounded form is expensive). Always consult a qualified clinician before any human use.

Is there anyone who should not use Tesamorelin + Ipamorelin?

Tesamorelin + Ipamorelin is FDA-approved, but no contraindications section was retrievable from its current label, so none is reproduced here. Consult the prescribing information and a qualified clinician before any human use.

How does Tesamorelin + Ipamorelin work?

The mechanism of action reported for Tesamorelin + Ipamorelin in the literature: Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover..

What is Tesamorelin + Ipamorelin studied for?

Tesamorelin + Ipamorelin has been studied in the published literature for: Visceral adiposity reduction (Tesamorelin signal); improved sleep and recovery; cleaner side-effect profile than CJC-DAC blends; favoured for HIV-lipodystrophy-adjacent body composition goals. These are areas of research, not established clinical uses unless the compound is FDA-approved for them.

What is Tesamorelin + Ipamorelin?

Tesamorelin + Ipamorelin is classified as: FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend. Also known as: Tesa+Ipa; long-acting GHRH + selective GHRP blend.

Drug class

Research focus area

All peptides studied for Growth Hormone Secretion, ranked by evidence tier and regulatory status.

Primary sources

  1. FDA Egrifta (tesamorelin) prescribing information
  2. Falutz J et al. Effects of tesamorelin (a GHRH analog) in HIV-associated abdominal fat accumulation. N Engl J Med 2007. PMID 18046027
  3. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. PMID 9849822

Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.

Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.

Loading interactive view…